Saving Sponsors Time And Money From Preclinical To Clinical

In this interview, Steve Mason, Co-Chief Operating Officer at Altasciences, discusses the company's approach to accelerating drug development timelines through an integrated preclinical-to-clinical model. Traditional drug development often involves multiple CROs and consultants, creating bottlenecks and delays as data transitions between stages. Altasciences streamlines this process by managing everything in-house, enabling seamless communication and data flow. This approach eliminates barriers, allowing preclinical and clinical teams to collaborate in real time and make decisions faster. Mason explains how Altasciences can reduce development timelines by approximately 30%, not by cutting study durations but by accelerating data interpretation, decision-making, and regulatory preparation.

By optimizing processes like IND application drafting and clinical protocol development, Altasciences delivers significant time and cost savings for sponsors, ensuring a faster path from preclinical studies to clinical trials while maintaining regulatory and scientific rigor.